ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 21 of 55
Up
JMBS 2022, 7(5): 134–139
https://doi.org/10.26693/jmbs07.05.134
Clinical Medicine

The Development of Leukemia after a Sustained COVID-19 Infection

Khaniukov O. O., Pisotska L. A., Bucharskyi O. V., Shchukina O. S.
Abstract

The purpose of the study was to review the literature on cases of leukemia in healthy people after the COVID-19 infection with a description of our own observation. Materials and methods. 26 literature sources were reviewed and analyzed using the PubMed/MEDLINE database regarding diagnosis of the leukemic process in patients after COVID-19. Analytical and bibliosemantic methods were used in the research. Results and discussion. Many aspects of the COVID-19 infection, especially its complications and long-term health consequences, are still unknown. Various reactive changes in blood tests during COVID-19 have been published. Leukocytosis, leukopenia, neutrophilia, lymphocytosis and lymphocytopenia, thrombocytopenia and rarely thrombocytosis were most often detected. The detected changes were usually not observable in patients. There are reports of leukemia after a recent COVID-19. Therefore, studying the features of the clinical picture and hematopoiesis in such patients during a viral infection, as well as at the initial manifestations of leukemia, is relevant. Costa B. and co-authors report cases of the development of the leukemic process in previously healthy young patients. Patients are aged 31-35 years with normal blood tests, in whom the manifestation of leukemia appeared approximately 2-3 months after COVID-19. The course of COVID-19 was not severe in all. Mild microcytaria was detected in one case of hypochromic anemia. The development of malignant hematological diseases in these patients with an unfavorable prognosis for the course and response to treatment attracts attention. These was T-cell acute lymphoblastic leukemia, myelodysplastic syndrome, acute myeloid leukemia with trigeminal dysplasia in the bone marrow, suggesting previous myelodysplastic syndrome. Nekooghadam S. M. and co-authors presented a case of acute myeloid leukemia in a man after recovery from COVID-19 after 1.5 months. The course of the infection was severe. The blood test showed slight leukocytosis. Manifestations of the described cases of leukemia included clinical gastroenteropathy and anemic syndrome. Two- or three-fold severe pancytopenia and dysplasia were more common in the analysis of bone marrow hematopoiesis. Low blastemia was a feature. Some authors suggest that SARS-Cov-2 plays a role in leukogenesis. The leading role in this is attributed to the imbalance of the renin-angiotensin system caused by the virus, which triggers leukogenesis in several mechanisms. An abnormal immune response to a viral infection can trigger secondary mutational events, contributing to the clinical development of leukemia. In addition to the effect of SARS-CoV-2 on renin-angiotensin system, other mechanisms of the potential development of cancer may underlie it. In particular, COVID-19 has been associated with T-cell exhaustion and activation of oncogenic pathways, including JAK-STAT, MAPK, and NF-kB. The coronavirus non-structural protein stabilizes factors by increasing RCHY1-mediated apoptosis-associated degradation of p53. The case of an acute leukemic process described by us was distinguished by a rapid atypical course, neurological symptoms, pancytopenia in peripheral blood during hospitalization, and a changed linear morphology of blast cells. Conclusion. According to the literature, the leukemic process after a sustained COVID-19 more often has an acute myeloid variant with hematopoietic dysplasia and a severe atypical course. Hematological monitoring of patients who have undergone COVID-19 in the presence of an oncology history or changes in the blood test during recovery from it is necessary. It is advisable to have a control of the hemogram after 2-3 months

Keywords: COVID-19, hematological complications, leukemia, clinical case

Full text: PDF (Ukr) 0P

References
  1. Lippi G, Plebani M. The critical role of Laboratory Medicine during coronavirus disease 2019 (covid-19) and other viral outbreaks. Clin Chem Lab Med (CCLM). 2020;58(7):1063-9. PMID: 32191623. https://doi.org/10.1515/cclm-2020-0240
  2. Eastin C, Eastin T. Clinical Characteristics of Coronavirus Disease 2019 in China. J Emerg Med. 2020;58(4):711-712. PMCID: PMC7266766. https://doi.org/10.1016/j.jemermed.2020.04.004
  3. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Int Med. 2020;180(7):934-943. PMID: 32167524. PMCID: PMC7070509. https://doi.org/10.1001/jamainternmed.2020.0994
  4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. PMID: 32031570. PMCID: PMC7042881. https://doi.org/10.1001/jama.2020.1585
  5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
  6. Chen W, Lin Y, Huang H, Cai M, Lin D, Su M, et al. A Retrospective Study of the Epidemiologic and Clinical Characteristics of COVID-19 Among Hospitalized Patients in Quanzhou, China. Infectious Microbes Dis. 2021;3(1):32-40. PMCID: PMC8011347. https://doi.org/10.1097/IM9.0000000000000048
  7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848. PMID: 32125452. PMCID: PMC7080116. https://doi.org/10.1007/s00134-020-05991-x
  8. Lippi G, Plebani M, Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145-148. PMID: 32178975. PMCID: PMC7102663. https://doi.org/10.1016/j.cca.2020.03.022
  9. Qu R, Ling Y, Zhang Y, Wei L, Chen X, Li X, et al. Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19. J Med Virol. 2020;92(9):1533-1541. PMID: 32181903. PMCID: PMC7228291. https://doi.org/10.1002/jmv.25767
  10. Costa B, da Luz K, Campos S, Lopes G, Leitão J, Duarte F. Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature. Hematol Transfus Cell Ther. 2022;44(1):26-31. PMID: 35075445. PMCID: PMC8768508. https://doi.org/10.1016/j.htct.2021.11.015
  11. Nekooghadam SM, Moradi A, Karimi Toudeshki K, Pishgahi M. A Case of Acute Leukemia Following Remission of COVID-19 Infection; an Urge to Search for a Probable Association. Arch Acad Emerg Med. 2021 Jul 24;9(1):e51.
  12. Lanza K, Perez L, Costa L, Cordeiro T, Palmeira V, Ribeiro V, et al. Covid-19: the renin-angiotensin system imbalance hypothesis. Clin Sci. 2020;134(11):1259-1264. PMID: 32507883. PMCID: PMC7276636. https://doi.org/10.1042/CS20200492
  13. Haznedaroglu I, Beyazit Y. Review: Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. J Renin Angiotensin Aldosterone Syst. 2010;11(4):205-213. PMID: 20807797. https://doi.org/10.1177/1470320310379876
  14. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of covid-19. Nat Med. 2020;26(7):1017-32. PMID: 32651579. https://doi.org/10.1038/s41591-020-0968-3
  15. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-COV-2. Nature. 2020;581(7807):221-4. PMID: 32225175. PMCID: PMC7328981. https://doi.org/10.1038/s41586-020-2179-y
  16. Rivellese F, Prediletto E. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmun Rev. 2020;19(6):102536. PMID: 32251718. PMCID: PMC7195011. https://doi.org/10.1016/j.autrev.2020.102536
  17. Zhang Y, Zeng X, Jiao Y, Li Z, Liu Q, Ye J, et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res. 2020;193:110-115. PMID: 32535232. PMCID: PMC7274097. https://doi.org/10.1016/j.thromres.2020.06.008
  18. Cheng H, Wang Y, Wang G. Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19. J Med Virol. 2020;92(7):726-730. PMID: 32221983. PMCID: PMC7317908. https://doi.org/10.1002/jmv.25785
  19. Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018;18(8):471-484. PMID: 29784935. PMCID: PMC6986894. https://doi.org/10.1038/s41568-018-0015-6
  20. Ciftciler R, Haznedaroglu IC. Pathobiological interactions of local bone marrow renin-angiotensin system and central nervous system in systemic arterial hypertension. Front Endocrinol (Lausanne). 2020 Aug 7;11:425. PMID: 32903745. PMCID: PMC7438890. https://doi.org/10.3389/fendo.2020.00425
  21. Beyazit Y, Aksu S, Haznedaroglu IC, Kekilli M, Misirlioglu M, Tuncer S, et al. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J Natl Med Assoc. 2007 Jan;99(1):57-63. PMID: 17304969. PMCID: PMC2569610
  22. De la Iglesia Iñigo S, López-Jorge CE, Gómez-Casares MT, Lemes Castellano A, Martín Cabrera P, López Brito J, et al. Induction of apoptosis in leukemic cell lines treated with Captopril, trandolapril and losartan: A new role in the treatment of leukaemia for these agents. Leuk Res. 2009;33(6):810-6. PMID: 19010543. https://doi.org/10.1016/j.leukres.2008.09.029
  23. Kozako T, Soeda S, Yoshimitsu M, Arima N, Kuroki A, Hirata S, et al. Angiotensin ii type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult t‐cell leukemia cells. FEBS Open Bio. 2016;6(5):442-60. PMID: 27419050. PMCID: PMC4856423. https://doi.org/10.1002/2211-5463.12055
  24. Saini G, Aneja R. Cancer as a prospective Sequela of Long Covid‐19. BioEssays. 2021;43(6):2000331. PMID: 33914346. PMCID: PMC8206711. https://doi.org/10.1002/bies.202000331
  25. Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. Covid-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021;90:107247. PMID: 33307513. PMCID: PMC7709613. https://doi.org/10.1016/j.intimp.2020.107247
  26. Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, et al. P53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PL pro via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci U S A. 2016;113(35). PMID: 27519799. PMCID: PMC5024628. https://doi.org/10.1073/pnas.1603435113